

## Curriculum Vitae

<b>Name</b>	Philip John BARTER
<b>NATIONALITY</b>	Australian
<b>DEGREES AND QUALIFICATIONS</b>	MB BS (1964) (Adelaide); PhD (1972) (ANU); MRACP (1969); FRACP (1977)
<b>CLINICAL AND RESEARCH TRAINING</b>	Royal Adelaide Hospital; Canberra Hospital; Australian National University

### Positions held

(a) <b>Current Position</b>	Conjoint Professor School of Medical Sciences Faculty of Medicine University of New South Wales Sydney, AUSTRALIA
(b) <b>Past Positions</b>	
1972-1973	Assistant Professor in Medicine, University of Iowa, USA
1973-1974	Visiting Fellow, Cardiovascular Research Institute, University of California, USA
1974-1979	Senior Lecturer in Clinical Biochemistry, Flinders University of South Australia, School of Medicine
1979-1986	Reader, Clinical Biochemistry, Flinders University of South Australia, School of Medicine
1986-1990	Deputy Director, Baker Medical Research Institute, Prahran, Victoria
1990- 1992	Professor of Preventive Cardiology and Head of the Graduate School of Health and Medical Sciences, The University of Wollongong.
1992-2003	Knapman-NHF Professor of Cardiology, The University of Adelaide
1996- 2000	Academic Dean, Faculty of Medicine, University of Adelaide
2002-2003	Director, Hanson Institute, Adelaide, Australia

2003-2012 Director, The Heart Research Institute, Sydney,  
and Professor of Medicine, University of  
Sydney

## **Awards**

European Atherosclerosis Society Anitschkow Award for 2011.

2013 Australian Heart Foundation Research Medal for Lifetime Contribution to  
Cardiovascular Research

## **Scientific and professional bodies**

### **Australian Society for Medical Research**

1972- ongoing Member  
1979 Director

### **Australian Atherosclerosis Society**

1976- ongoing Member  
1986-1988, 1993-1996 Chairman  
1998-2003 Treasurer

### **National Heart Foundation of Australia**

1976-1979, 1989-1997 Member, Diet and Heart Disease Committee  
1996-1997 Chairman, Diet and Heart Disease Committee  
1977-1992 Member, National Medical and Scientific  
Advisory Committee  
1986-1992 Chairman, National Medical and Scientific  
Advisory Committee  
1985-1988, 1997-1999 Chairman, Grants Committee  
1986-1992 Member, Board of Directors  
1992-1997 Chairman, Lipid Study Data and Safety  
Monitoring Committee  
1997-2003 Member, Cardiovascular Health Advisory  
Committee  
1998-2001 Chairman, Nutrition and Metabolism Advisory  
Committee  
2002-ongoing Chairman, Nutrition and Metabolism Advisory  
Committee  
1999-2003 Chairman, Research Committee

### **National Health and Medical Research Council**

1977-1984, 1992-1999 Member, RGIC  
1982-1987 Member, Scholarships Committee  
1998-1999 Chairman, RGIC  
2004 Member, Postgraduate Scholarship Panel  
2005 Member GRP 6b - Cardiovascular/ Renal/  
Sports Medicine

### **Cardiac Society of Australia and New Zealand**

1994-ongoing Member

**American Heart Associations Council on Arteriosclerosis**  
1972-ongoing Fellow

**International Task Force for Prevention of Coronary Heart Disease**  
2003-ongoing Member, Board of Directors

**Future Forum and Future Forum Editorial Board**  
1999-ongoing Member  
2001-2004 Chairman  
2005-ongoing Member

**AZTECC** (An international training program for emerging opinion leaders)  
2001-2007 Chairman

**Metabolic Syndrome Institute (International)**  
2003-2004 Chairman

**International Atherosclerosis Society**  
1990-ongoing Member  
1999-ongoing Member, Strategic and Long Term Planning  
Committee  
2003-ongoing Member, International Executive  
2006-2009 Secretary  
2010-2012 President Elect  
2013-2015 President

## Competitive research grants

1975-1976	Grant-in-Aid, National Heart Foundation \$10,500 per annum
1977-1978	Grant-in-Aid, National Heart Foundation \$8,000 per annum
1979	Grant-in-Aid, NHMRC \$12,000
1978	Grant-in-Aid, NHMRC \$7,000
1978-1980	Grant-in-Aid, NHMRC \$15,000 per annum
1979	Grant-in-Aid, National Heart Foundation \$5,000
1980-1981	Grant-in-Aid, National Heart Foundation \$17,000 per annum
1980-1982	Grant-in-Aid, NHMRC \$34,000 per annum
1981-1982	Grant-in-Aid, NHMRC \$17,000 per annum

1981-1982	Grant-in-Aid, NHMRC \$30,000 per annum
1982-1983	Grant-in-Aid, National Heart Foundation \$24,000 per annum
1983-1987	Program grant, NHMRC \$250,000 per annum
1984-1985	Grant-in-Aid, National Heart Foundation \$24,000 per annum
1986-1988	Grant-in-Aid, National Heart Foundation \$30,000 per annum
1989-1991	Grant-in-Aid, National Heart Foundation \$35,000 per annum
1987-1991	Block Grant from the NHMRC to the Baker Institute \$250,000 per annum
1990-1991	Grant-in-Aid, National Heart Foundation \$36,000 per annum
1991-1993	Grant-in-Aid, NHMRC \$120,000 per annum
1991	Grant-in-Aid from Ramaciotti Foundation \$40,430 (Equipment Grant)
1991	Grant-in-Aid, National Heart Foundation \$40,000 (Equipment Grant)
1992	Grant-in-Aid from Ramaciotti Foundation \$20,000 (Equipment Grant)
1992	Equipment Grant from J-Fund, SA Division of National Heart Foundation. \$46,500
1993-1995	Grant-in-Aid, National Heart Foundation \$55,000 per annum
1994-1996	Grant-in-Aid, NHMRC \$38,000 per annum
1995	Grant-in-Aid, Hoechst Diabetes Research and Development Grants. \$30,000
1995	Ramaciotti Foundation. \$10,000
1996-1998	Grant-in-Aid, NHMRC \$75,000 per annum
1996-97	Grant-in-Aid, National Heart Foundation \$50,000 per annum
1996	RAH Research Review Committee. \$22,000
1997-2001	Grant-in-Aid, NHMRC \$122,000 per annum
1998-1999	Grant-in-Aid, National Heart Foundation

	\$33,000 per annum
2000-2002	Grant-in-Aid, NHMRC \$98,000 per annum
2000-2001	Grant-in-Aid, National Heart Foundation \$36,000 per annum
2001-2002	Pfizer International HDL award US\$100,000 per annum
2002	Grant-in-Aid, NHMRC \$75,000 per annum
2003-2007	Program Grant, NHMRC \$1,300,000 per annum
2003 -2004	Pfizer International HDL award US\$100,000 per annum
2006-2008	Discovery-Project \$120,000 per annum
2008-2012	Program Grant, NHMRC \$1,806,516 per annum
2011-2013	Project Grant, NHMRC \$153,000 per annum
2013-2017	Program grant, NHMRC \$1,480,000 per annum

## Leadership of seminal clinical trials

**1992-1997**

### **LIPID Study**

Chairman, data and safety monitoring committee,  
The LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) Study was a large-scale, prospective, five-year, double-blind, placebo controlled trial of about 10,000 subjects in Australia and New Zealand. It established that treatment with the cholesterol-lowering drug, pravastatin, significantly reduced coronary mortality and total death. This study has greatly influenced clinical practice world-wide.

**2002-2007**

### **Pearl Study**

Member, data and safety monitoring committee,  
The Pearl Study is a large-scale, prospective, three-year, multicentre, double-blind, placebo controlled trial of 7,500 women. It is designed to determine whether the drug lasofoxifene reduces the development of osteoporosis and breast cancer. This study is being conducted in multiple centres in the USA and Europe.

**1997-2005**

### **FIELD study**

Member of the Executive of the Steering Committee,  
The FIELD study is a large-scale, prospective, five-year, double-blind, placebo controlled trial of almost 10,000 subjects with

diabetes. It is designed to determine the effect of the drug fenofibrate on the rate of coronary events and coronary death. This study is being conducted in multiple centres in Australia, New Zealand and Finland It has the potential to influence greatly the way people with diabetes are treated.

**1998-2005**

**TNT trial**

Member of the Executive of the Steering Committee,

The TNT (Treatment To new Targets) study is a large-scale, prospective, five-year, double-blind, placebo controlled trial of almost 10,000 subjects with coronary heart disease. It is designed to determine the effect of moderate versus aggressive lipid lowering on the rate of coronary events and coronary death. This study is being conducted in multiple centres in the USA, Europe, South Africa and Australia. The study has the potential to influence greatly the way people with CHD are treated.

**1999-2004**

**GEMS Study (International genetics study)**

Member of the Executive of the Steering Committee,

The GEMS study is a large international study designed to identify the genes associated with susceptibility to the Metabolic Syndrome.

**2004-2008**

**ILLUMINATE Trial (Torcetrapib/Atorvastatin Morbidity and Mortality Trial)**

Chairman of Steering Committee,

This international trial (15,000 people) to test the protective effects of inhibiting CETP was terminated early because of an excess mortality and cardiovascular events in the group treated with torcetrapib.

**2008-2010**

**DEFINE Trial (Assessing the safety of the CETP inhibitor, anacetrapib))**

Co-Chairman of Steering Committee,

This 18 month, 1,500 person international trial was designed to assess the safety of anacetrapib prior to embarking on a large cardiovascular endpoint trial.

**2008-2012**

**DalOUTCOME Trial (Assessing the cardiovascular protective effects of the CETP inhibitor, dalcetrapib))**

Member of the Executive of the Steering Committee,

This 3 year, 15,000 person international trial involves ws designed to assess the cardiovascular protective properties of dalcetrapib. The trial was terminate prematurely for futility.

**2010-2013**

**CHI-SQUARE**

Member of the executive committee

This coronary intravascular ultrasound study is assessing the effects of a preparation of reconstituted HDL on coronary atheroma burden.

**2011-2015**

**REVEAL Trial**

Member of the Steering Committee.

This 4 year, 30,000-person international trial is designed to assess the cardiovascular protective properties of anacetrapib.

**2012-2016**

**ACCELERATE Trial**

Member of the Steering Committee.

This 4 year, 11,000-person international trial is designed to assess the cardiovascular protective properties of evacetrapib.

**Postgraduate students supervised**

BA Dilena	1978-1979	MSc:	Awarded 1979
Jl Lally	1977-1980	MSc:	Awarded 1980
OV Rajaram	1977-1979	PhD:	Awarded 1980
Ha Ying Chea	1978-1981	PhD:	Awarded 1981
M Abbey	1981-1984	PhD:	Awarded 1984
KA Rye	1983-1985	PhD:	Awarded 1986
PM Clifton	1984-1987	PhD:	Awarded 1987
MA Clay	1987-1990	PhD:	Awarded 1990
HH Newnham	1987-1990	PhD:	Awarded 1990
RJ Warren	1989-1992	PhD:	Awarded 1992
BJ Meyer	1989-1992	PhD:	Awarded 1993
Hui-Qi Liang	1992-1996	PhD:	Awarded 1997
D Ashby	1996-1998	PhD:	Awarded 1999
N Hime	1997-2001	PhD:	Awarded 2001
N Settasatian	1998-2001	PhD:	Awarded 2001
M Duong	1999-2003	PhD:	Awarded 2003
P Kee	1999-2003	PhD:	Awarded 2004
S Nicholls	2001-2003	PhD:	Awarded 2004
R Puranik	2004-2006	PhD:	Awarded 2007
B diBartolo	2005-2009	PhD:	Awarded 2009
S Patel	2006-2009	PhD:	Awarded 2010
G Reimers	2006-2009	PhD:	Awarded 2010
M Fryirs	2006-2009	PhD:	Awarded 2010
K Shearston	2007-2012	PhD:	Awarded 2012

**Invited participation in meetings (since 1997)**

**Invited plenary lectures**

**Year**

**International Meeting**

1997	<b>Invited plenary lecture</b> at the XIth International Symposium on Atherosclerosis, Paris, France. Antiatherogenic effects of high-density lipoproteins: mechanisms.
2001	<b>Invited plenary lecture</b> at the XIVth International Symposium on Drugs Affecting Lipid Metabolism, New York, USA. Anti-inflammatory properties of high density lipoproteins.
2004	<b>Invited plenary lecture</b> at the 74 <sup>th</sup> EAS Congress, Seville, Spain (17-20

- April). Lecture on HDL and Diabetes
- 2004 **Invited plenary lecture** at the 4<sup>th</sup> Congress of Asian Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD), Bali, Indonesia (7 May ). Lecture on the Importance of remnant lipoprotein in atherogenesis.
- 2005 **Invited plenary lecture** at the 2<sup>nd</sup> International Symposium on Triglycerides and HDL in New York (July).
- 2006 **Invited plenary lecture** at the 38<sup>th</sup> Annual Meeting of the Heart Association Thailand, Bangkok (January).
- 2007 **Invited plenary lecture** at the European Atherosclerosis Society, Helsinki, Finland (June).
- Invited plenary lecture** at the 9<sup>th</sup> Hong Kong Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Hong Kong (October).
- Invited plenary lecture** at the XV<sup>th</sup> International Symposium on Drugs Affecting Lipid Metabolism, New York City, NY, USA (October).
- Invited plenary lecture** at the Scientific Sessions of the American Heart Association, Orlando, Florida, USA (November).
- Invited plenary lecture** at the Asian Pacific Congress of Cardiology, Taipei ,Taiwan (December).
- 2008 **Invited plenary lecture** at the 6<sup>th</sup> APSAVD East meets West 2008 meeting, Hong Kong (September) HDL-raising – how can this be achieved?
- 2009 **Invited plenary lecture** at the 15<sup>th</sup> International Symposium on Atherosclerosis, Boston, USA
- 2011 **Invited plenary lecture** at the 17<sup>th</sup> International Symposium on DRUGS AFFECTING LIPID METABOLISM: DIABETES, OBESITY, AND THE METABOLIC SYNDROME held in Doha, Qatar

### ***Named lecturer at international meeting***

- | <b>Year</b> | <b>International Meeting</b>   |
|-------------|--|
| 2001        | <b>Invited to present the Hugh Sinclair memorial lecture</b> at the annual scientific meeting of the British Atherosclerosis Society, Cambridge, UK. The regulation and remodelling of HDL by plasma factors. (This meeting was cancelled because of the events in New York on 11 September 2001). A paper of the presentation was published in Atherosclerosis Reports. |
| 2002        | <b>Invited to deliver the Esko Nikkila Lecture</b> at the annual meeting of the Finnish Internal Medicine Society, Helsinki, Finland.  |
| 2004        | <b>Invited to deliver the Myant Lecture</b> at the 18 <sup>th</sup> Annual Medical and Scientific Meeting of HEART, UK held in Bath on 2 July, 2004.   |



2011 **Invited to deliver the Anitschkow Lecture** at the 79th EAS Congress held in June 2011 in Gothenburg, Sweden.

***Invited speaker at major international meeting***

<b>Year</b>	<b>International Meeting</b>
1997	<b>Invited presentation</b> International Symposium on Diabetes and Atherosclerosis, Lyon, France. Role of CETP in diabetes.
1999	<b>Invited presentation</b> at the 71st European Atherosclerosis Meeting, Athens, Greece. Intravascular remodelling of high density lipoproteins
1999	<b>Invited presentation</b> at the 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease, Venice, Italy. Role of HDL in coronary heart disease.
2000	<b>Invited presentation</b> at the International Symposium: on HDL, Miami, Florida. Intravascular remodelling of HDL.
2000	<b>Invited presentation</b> at the International Symposium on The Role of HDL in Disease Prevention. Istanbul, Turkey. The FIELD Study
2000	<b>Invited presentation</b> at the Satellite Symposium of the XII <sup>th</sup> International Symposium on Atherosclerosis: "HDL and Reverse Cholesterol Transport", Helsinki, Finland. The protective role of HDL in atherosclerosis
2001	<b>Invited workshop presentation</b> at the First International Symposium on PPAR: from basic science to clinical implications. Florence, Italy. Anti-inflammatory properties of high density lipoproteins.
2001	<b>Invited presentation</b> at the annual meeting of the Japanese Atherosclerosis Society, Toyo, Japan. Anti-atherogenic properties of HDL
2002	<b>Invited lecture</b> at the 3rd Congress of the Asian-Pacific Society of Atherosclerosis, Cebu, Philippines. The Molecular Biology of Atherosclerosis
2002	<b>Invited lecture</b> at the First International Meeting on the Metabolic Syndrome, Lille, France. Causes and management of low HDL-C
2003	<b>Invited presentation</b> at the 3 <sup>rd</sup> International symposium on HDL: Dijon, France.
2003	<b>Invited presentation</b> at the International Atherosclerosis Symposium on diabetes in Lugano, Switzerland
2003	<b>Invited presentation</b> at the annual meeting of the Taiwn Society of cardiology in Taipei, Taiwan
2003	<b>Invited presentation</b> at the International Atherosclerosis Symposium in Kyoto Japan.
2004	<b>Invited lecture</b> at 1 <sup>st</sup> International Cardiovascular Research Conference, Marrakech, Morocco (19 May). Lecture on Mechanisms of HDL protection and the metabolic syndrome.
2004	<b>Invited lecture</b> at 7 <sup>th</sup> Annual Conference on Advances in Cardiology and Cardiovascular Therapeutics, Putrajaya, Malaysia (17 July). Lecture on Current thoughts about metabolic syndrome.
2004	<b>Invited lecture</b> at the Kern Aspen Lipid Conference the premier national meeting on lipids and atherosclerosis (21-24 August). Lecture on HDL and protection from atherosclerosis.

- 2004 **Invited lecture** at the 2004 HDL Workshop, Crete, Greece (2-6 September). Lecture on Mechanisms by which HDL protects against atherosclerosis.
- 2004 **Invited lecture** at the Future Forum Conference, Toronto, Canada (8-9 October). Lecture on The inflammation: lipoprotein cycle.
- 2005 **Invited presentation** at the 1st International Congress on `Prediabetes` and the Metabolic Syndrome- Epidemiology, Management and Prevention of Diabetes and Cardiovascular Disease, Berlin, Germany (13-16 April).
- 2005 **Invited speaker** at the 75<sup>th</sup> EAS Congress held in Prague, (April).
- 2005 **Invited presentation** at the 2<sup>nd</sup> NSFA (French Atherosclerosis Society Congress held in Biarritz, France (June).
- 2005 **Invited presentation** at the Cardiac Society of Australia and New Zealand 53<sup>rd</sup> Annual Scientific Meeting in Perth (August).
- 2005 **Invited lecture** at the meeting of the European Association for the Study of Diabetes (EASD) held in Athens, Greece (September, 2005).
- 2005 **Invited presentation** at the 2005 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland (23-24 September).
- 2006 **Invited presentation** at the XIV<sup>th</sup> International Symposium on Atherosclerosis, Rome, Italy (June).
- 2006 **Invited presentation** at the 66<sup>th</sup> Annual Scientific Sessions of the American Diabetes Association, Washington, DC, USA (June 9).
- 2006 **Invited presentation** at the Gordon Research Conference on Lipoprotein Metabolism, South Hadley, MA, USA (July).
- 2006 **Invited presentation** at the National Atherosclerosis Forum, Toronto, Canada (September).
- 2006 **Invited presentation** at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (August).
- 2007 **Invited presentation** at the Diabetes at the Limits Conference, Kyoto, Japan (March).
- 2007 **Invited presentation** at the Oxford Clinical Trials Group, USA (March).
- 2007 **Invited presentation** at the American College of Cardiology, New Orleans, USA (March).
- 2007 **Invited presentation** at the Future Forum Conference, Vienna, Austria (April).
- 2007 **Invited presentation** at the 2<sup>nd</sup> International Meeting on Prediabetes, Barcelona, Spain (April).
- 2007 **Invited presentation** at the 4<sup>th</sup> International Symposium on the Metabolic Syndrome, Diabetes and Atherosclerosis, Lisbon, Spain (May).
- 2007 **Invited presentation** at the Nordic Conference of Cardiology, Oulu, Finland (June).
- 2007 **Invited presentation** at the HDL Satellite of European Atherosclerosis Society, Helsinki, Finland (June).
- 2008 **Invited presentation** entitled `New developments in lipid-lowering therapy`

- at the CSANZ Meeting Adelaide, SA (June)
- 2008 **Invited presentations** entitled 'Fallacies from clinical trials: Dyslipidemia' and 'Treatment of atherosclerosis in diabetes: Role of statins' at the European Society of Cardiology Meeting, Munich, Germany August.
- 2008 **Invited presentation** entitled 'HDL overview and recent trials' at the 6<sup>th</sup> Annual Cardiovascular Biomarker and Surrogate Endpoint Symposium, Washington, DC, USA, September.
- 2009 **Invited presentation** entitled "Anti-inflammatory properties of HDL" at the 3<sup>rd</sup> International congress on prediabetes and the metabolic syndrome, Nice, France
- 2009 **Invited presentation** entitled "HDL Subpopulations – Targets for Future Atherosclerosis Prevention" at the annual scientific meeting of the Scandinavian Society for Atherosclerosis research, Copenhagen, Denmark
- 2009 **Invited presentation** entitled "Enlightenment from ILLUMINATE" at the annual meeting of the European Society of Cardiology in Barcelona, Spain
- 2011 **Invited presentation** at the 4th International Meeting on Prediabetes, and the Metabolic Syndrome held in Madrid, Spain
- 2011 **Invited presentation** at the 2011 Atherosclerosis Gordon Research Conference, held in Newport, RI, USA
- 2011 **Invited presentation** at 2011 Meeting of the European Society of Cardiology held in August 2011 in Paris, France.
- 2011 **Invited presentation** at a meeting of the Royal Society of Medicine: Section on Lipids: Recipient of the President's Medal and Lecture given in December 2011 in London, UK.
- 2012 **Invited presentation** at the ISA Satellite on HDL held in Cairns in April 2012
- 2012 **Invited presentation** at the International Congress on Abdominal Obesity held in July 2012 in Quebec City
- 2012 **Three invited presentations** at the 2012 Meeting of the European Society of Cardiology held in August 2012 in Munich, Germany
- 2012 **Invited presentation** at the annual meeting of the American Heart Association Los Angeles in November 2012
- 2013 **Invited presentation** at the International Cardiology Symposium in Dubai, United Arab Emirates held in May 2013

- 2013 **Invited presentation** at the Satellite Symposium of WCN 2013 Kidney and Lipids held in Fukuoka, Japan in June 2013
- 2013 **Invited presentation** at the 14th Brazilian Congress of Atherosclerosis held in Sao Paulo, Brazil in August 2013
- 2013 **Three invited presentations** at the 2013 Meeting of the European Society of Cardiology held in August 2013 in Amsterdam, Holland
- 2013 **Invited presentation** at the International Congress on Abdominal Obesity held in September 2013 in Seoul, Korea
- 2013 **Invited presentation** at the Annual Scientific Meeting of Taiwan Society of Lipids & Atherosclerosis held in Taipei, Taiwan in September 2013
- 2013 **Invited presentation** at the Annual scientific meeting of the American Heart Association in Dallas in November 2013
- 2014 **Two invited presentations** at the Annual Scientific Meeting of the American College of Cardiology in Washington DC
- 2014 **Two invited presentations** at the World Congress of Cardiology in Melbourne, Australia
- 2015 **Two invited presentation** at the ISA meeting held in Amsterdam
- 2015 **Two invited presentations** at the Annual Scientific Meeting of the American College of Cardiology in San Diego
- 2015 **Three invited presentations** at the Annual scientific meeting of the American Heart Association in Orlando
- 2016 **Invited presentation** at the European Society of Cardiology meeting in Rome
- 2016 **Three invited presentations** at the Annual Scientific Meeting of the American College of Cardiology in New Orleans

### **Membership of editorial boards of scientific journals**

1997-2008	Atherosclerosis
2000-1012	Arteriosclerosis, Thrombosis and Vascular Biology
2000-2012	Current Clinical Trials in Cardiovascular Disease
1999-2000	Section Editor, Current Opinion in Lipidology
2002-ongoing	Nutrition, Metabolism and Cardiovascular Diseases

### **Reviewer for the following journals:**

*Arterioscler Thromb Vasc Biol* (30-40 papers per year); *Atherosclerosis* (10-15 per year); *J Lipid Res* (8 per year); *J Am Coll Cardiol* (3-5 per year); *Circulation* 10 per year); *FASEB J* (1-2 per year); *Journal of Clinical Investigation* (4-5 per year); other journals (4-5 per year). Overall, about 100 papers per year.

## Publications

### *Papers in refereed journals*

1. Barter, PJ and Nestel, PJ. 'The distribution of triglyceride in subclasses of very low density lipoproteins', *J Lab Clin Med*, 1970, 76:925-932
2. Barter, PJ, Carroll, KF and Nestel, PJ. 'Diurnal fluctuations in triglyceride, free fatty acids, and insulin during sucrose consumption and insulin infusion in man', *J Clin Invest*, 1971, 50 583-591
3. Nestel, PJ and Barter, P. 'Metabolism of palmitic and linoleic acids in man: differences in turnover and conversion to glycerides', *Clin Sci*, 1971, 40:345-350
4. Barter, PJ and Nestel, PJ. 'Plasma free fatty acid transport during prolonged glucose consumption and its relationship to plasma triglyceride fatty acids in man', *J Lipid Res*, 1972, 13:483-490
5. Barter, PJ and Nestel, PJ. 'Precursor-product relationship between pools of very low density lipoprotein triglyceride', *J Clin Invest*, 1972, 51:174-180
6. Barter, PJ, Nestel, PJ and Carroll, KF. 'Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration and alcoholic fatty liver', *Metabolism*, 1972, 21:117-124
7. Barter, PJ and Nestel, PJ. 'Precursors of plasma triglyceride fatty acids in obesity', *Metabolism*, 1973, 22:779-785
8. Nestel, PJ and Barter, PJ, 'Triglyceride clearance during diets rich in carbohydrate or fats', *Am J Clin Nutr*, 1973, 26:241-245
9. Barter, PJ. 'Origin of esterified cholesterol transported in the very low density lipoproteins of human plasma', *J Lipid Res*, 1974, 15:11-19
10. Barter, PJ. 'Production of plasma esterified cholesterol in lean, normotriglyceridemic humans', *J Lipid Res*, 1974, 15:234-242
11. Barter, PJ, Connor, WE, Spector, AA, Armstrong, M, Connor, SL and Newman, MA. 'Lowering of serum cholesterol and triglyceride by para-aminosalicylic acid in hyperlipoproteinemia: studies in patients with types II-A and II-B', *Ann Intern Med*, 1974, 81:619-624
12. Barter, PJ and Connor, WE. 'The transport of triglyceride in the high-density lipoproteins of human plasma', *J Lab Clin Med*, 1975, 85:260-272
13. Barter, PJ and Connor, WE. 'The transport of esterified cholesterol in plasma high density lipoproteins of human subjects: a mathematical model', *J Lab Clin Med*, 1976, 88:627-639
14. Barter, P, Faergeman, O. and Havel, RJ. 'Metabolism of cholesteryl esters of very low density lipoproteins in the guinea pig', *Metabolism*, 1977 26:615-622

15. Barter, PJ and Lally, JI. 'Metabolism of esterified cholesterol in the plasma very low density lipoproteins of the rabbit: studies in vivo and in vitro', *Atherosclerosis*, 1978, 31:355-364
16. Barter, PJ and Lally, JI. 'The activity of an esterified cholesterol transferring factor in human and rat serum', *Biochimica et Biophysica Acta*, 1978, 531:233-236
17. Barter, PJ Gooden, JM and Rajaram, OV. 'Species differences in the activity of a serum triglyceride transferring factor', *Atherosclerosis*, 1979, 33:165-169
18. Barter, PJ and Jones, ME. 'Rate of exchange of esterified cholesterol between human plasma low and high density lipoproteins', *Atherosclerosis*, 1979, 34:67-74
19. Barter, PJ, and Lally, JI. '*In vitro* exchanges of esterified cholesterol between serum lipoprotein fractions: studies of humans and rabbits', *Metabolism*, 1979, 28:230-236
20. Barter, PJ and Lally, JI. 'The metabolism of esterified cholesterol in rabbit plasma low density lipoproteins', *Biochimica et Biophysica Acta*, 1979, 572:510-518
21. Barter, PJ, Lally, JI and Wattchow, D. 'Metabolism of triglyceride in rabbit plasma low and high density lipoproteins: studies in vivo and in vitro', *Metabolism*, 1979, 28:614-618
22. Ha, YC, Calvert, GD and Barter, PJ. 'In vivo metabolism of esterified cholesterol and apoproteins in rabbit plasma low density lipoproteins', *Atherosclerosis*, 1979, 34:451-455
23. Lally, JI and Barter, PJ. 'The in vivo metabolism of esterified cholesterol in the plasma high-density lipoproteins of rabbits', *J Lab Clin Med*, 1979, 93:570-582
24. Barter, PJ, Gorjatschko, L and Calvert, GD. 'Net mass transfer of esterified cholesterol from human low density lipoproteins to very low density lipoproteins incubated in vitro', *Biochimica et Biophysica Acta*, 1980, 619:436-439
25. Barter, PJ and Jones, ME. 'Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins', *J Lipid Res*, 1980, 21:238-249
26. Hopkins, GJ and Barter, PJ. 'Transfers of esterified cholesterol and triglyceride between high density and very low density lipoproteins: in vitro studies of rabbits and humans', *Metabolism*, 1980, 29:546-550
27. Rajaram, OV and Barter, PJ. 'Influence of lipoprotein concentration on the exchanges of triacylglycerol between rabbit plasma low density and high density lipoproteins', *Biochimica et Biophysica Acta*, 1980, 620:483-488

28. Rajaram, OV, Clark, MG and Barter, PJ. 'Differences in the metabolism of very-low-density lipoproteins by isolated beating-heart cells and the isolated perfused rat heart: evidence for collagenase-related extracellular lipoprotein lipase', *Biochem J*, 1980, 186:431-438
29. Rajaram, OV, White, GH and Barter, PJ. 'Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum', *Biochimica et Biophysica Acta*, 1980, 617:383-392
30. Barter, PJ, Ha, YC and Calvert, GD. 'Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins', *Atherosclerosis*, 1981, 38:165-175
31. Ha, YC, Calvert, GD, McIntosh, GH and Barter, PJ. 'A physiological role for the esterified cholesterol transfer protein: in vivo studies in rabbits and pigs', *Metabolism*, 1981, 30:380-383
32. Williams, DR, Barter, PJ and MacKinnon, AM. 'Serum lecithin:cholesterol acyltransferase activity in the bile duct-ligated rat', *Digestion*, 1981, 21:273-278
33. Barter, PJ, Gorjatschko, L and Hopkins, GJ. 'Comparison of different methods of isotopically labelling the esterified cholesterol in human high density lipoproteins', *Biochimica et Biophysica Acta*, 1982, 710:349-358
34. Barter, PJ, Hopkins, GJ and Calvert, GD. 'Pathways for the incorporation of esterified cholesterol into very low density and low density lipoproteins in plasma incubated in vitro', *Biochimica et Biophysica Acta*, 1982, 713:136-148
35. Barter, PJ, Hopkins, GJ, Gorjatschko, L and Jones, ME. 'A unified model of esterified cholesterol exchanges between human plasma lipoproteins', *Atherosclerosis*, 1982, 44:27-40
36. Ha, YC and Barter, PJ. 'Differences in plasma cholesterol ester transfer activity in sixteen vertebrate species', *Comparative Biochem Physiol*, 1982, 71B:265-269
37. Hopkins, GJ and Barter, PJ. 'Dissociation of the in vitro transfers of esterified cholesterol and triglyceride between human lipoproteins', *Metabolism*, 1982, 31:78-81
38. Hopkins, GJ and Barter, PJ. 'An effect of very low density lipoproteins on the rate of cholesterol esterification in human plasma', *Biochimica et Biophysica Acta*, 1982, 712:152-160
39. Barter, PJ. 'Evidence that lecithin:cholesterol acyltransferase acts on both high-density and low-density lipoproteins', *Biochimica et Biophysica Acta*, 1983, 751:261-270
40. Barter, PJ and Hopkins, GJ. 'Relative rates of incorporation of esterified cholesterol into human very low density lipoproteins and low density

lipoproteins: in vitro studies of two separate pathways', *Biochimica et Biophysica Acta*, 1983, 751:33-40

41. Ha, YC, Gorjatschko, L and Barter, PJ. 'Changes in the density distribution of pig high density lipoproteins during incubation in vitro: influence of esterified cholesterol transfer activity', *Atherosclerosis*, 1983, 48:253-263
42. Hopkins, GJ and Barter, PJ. 'Role of esterified cholesterol transfers in the regulation of plasma cholesterol esterification', *Atherosclerosis*, 1983, 49:177-185
43. Abbey, M, Calvert, GD and Barter, PJ. 'Changes in lipid and apolipoprotein composition of pig lipoproteins facilitated by rabbit lipid transfer protein', *Biochimica et Biophysica Acta*, 1984, 793:471-480
44. Abbey, M, Savage, JK, MacKinnon, AM, Barter, PJ and Calvert, GD. 'Detection of lipid transfer protein activity in rabbit liver perfusate', *Biochimica et Biophysica Acta*, 1984, 793:481-484
45. Barter, PJ, Hopkins, GJ and Gorjatschko, L. 'Comparison of human plasma low- and high-density lipoproteins as substrates for lecithin:cholesterol acyltransferase', *Biochimica et Biophysica Acta*, 1984, 792:1-5
46. Barter, PJ, Hopkins, GJ, Gorjatschko, L and Jones, ME. 'Competitive inhibition of plasma cholesterol esterification by human high-density lipoprotein-subfraction 2', *Biochimica et Biophysica Acta*, 1984, 793:260-268
47. Ha, YC, Chang, LBF and Barter, PJ. 'Incubation of human lipid transfer protein with plasma from normal-fed and cholesterol-fed rats: effect on the distribution of constituents between lipoprotein fractions', *Comparative Biochem Physiol*, 1984, 78B:675-682
48. Hopkins, GJ and Barter, PJ. 'Capacity of lipoproteins to act as substrates for lecithin:cholesterol acyltransferase: enhancement by preincubation with an artificial triacylglycerol emulsion', *Biochimica et Biophysica Acta*, 1984, 794:31-40
49. Moon, EA, MacKinnon, AM and Barter, PJ. 'Appearance of serum amyloid protein in high-density lipoproteins of rabbits subjected to relatively mild stimuli', *Biochimica et Biophysica Acta*, 1984, 796:354-358
50. Rye, K-A. and Barter, PJ. 'Evidence of the existence of a high density lipoprotein transformation factor in pig and rabbit plasma', *Biochimica et Biophysica Acta*, 1984, 795:230-237
51. Barter, PJ, Hopkins, GJ and Gorjatschko, L. 'Lipoprotein substrates for plasma cholesterol esterification: influence of particle size and composition of the high density lipoprotein subfraction 3', *Atherosclerosis*, 1985, 58:97-107
52. Chang, L. B. F., Hopkins, G. J. and Barter, P. J., 'Particle size distribution of high density lipoproteins as a function of plasma triglyceride concentration in human subjects', *Atherosclerosis*, 1985, 56:61-70



53. Clifton, P. M., MacKinnon, A. M. and Barter, P. J., 'Effects of serum amyloid A protein (SAA) on composition, size and density of high density lipoproteins in subjects with myocardial infarction', *J Lipid Res*, 1985, 26:1389-1398
54. Ha, Y. C. and Barter, P. J., 'Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel superose 6B', *J Chromatog*, 1985, 341:154-159
55. Ha, Y. C., Chang L., B. F. and Barter, P. J., 'Effect of injecting exogenous lipid transfer protein into rats', *Biochimica et Biophysica Acta*, 1985, 833:203-210
56. Hopkins, G. J., Chang, L. B. F. and Barter, P. J., 'Role of lipid transfers in the formation of a subpopulation of small high density lipoproteins', *J Lipid Res*, 1985, 26:218-229
57. MacKinnon, A. M., Savage, J., Gibson, R. A. and Barter, P. J., 'Secretion of cholesteryl ester-enriched very low density lipoproteins by the liver of cholesterol-fed rabbits', *Atherosclerosis*, 1985, 54:145-155
58. Rajaram, O. V. and Barter, P. J., 'Reactivity of human lipoproteins with purified lecithin:cholesterol acyltransferase in vitro', *Biochimica et Biophysica Acta*, 1985, 835:41-49
59. Chang, L., Clifton, P., Barter, P. and MacKinnon, M., 'High density lipoprotein subpopulations in chronic liver disease', *Hepatology*, 1986, 6:46-49
60. Ha, Y. C. and Barter, P. J., 'Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteins', *Comparative Biochem Physiol*, 1986, 83B:463-466
61. Hopkins, G. J. and Barter, P. J., 'Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins', *J Lipid Res*, 1986, 27:1265-1277
62. MacKinnon, M., Savage, J., Wishart, R. and Barter, P., 'Metabolism of high density lipoproteins by the perfused rabbit liver', *J Biol Chem*, 1986, 261:2548-2552
63. Rajaram, O. V. and Barter, P. J., 'Increase in the particle size of high-density lipoproteins induced by purified lecithin:cholesterol acyltransferase: effect of low density lipoproteins', *Biochimica et Biophysica Acta*, 1986, 877:406-414
64. Rye, K-A., and Barter, P. J., 'Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor', *Biochimica et Biophysica Acta*, 1986, 875:429-438
65. Clifton, P. M., MacKinnon, A. M. and Barter, P. J., 'Separation and characterization of high-density lipoprotein subpopulations by gel permeation chromatography', *J Chromatog*, 1987, 414:25-34

66. Barter, P. J., Rajaram, O. V., Chang, L. B. F., Rye, K-A., Gambert, P., Lagrost, L., Ehnholm, C. and Fidge, N. H., 'Isolation of a high-density-lipoprotein conversion factor from human plasma: a possible role of apolipoprotein A-IV as its activator', *Biochem J*, 1988, 254:179-184
67. Clifton, P. M., Barter, P. J. and MacKinnon, A. M., 'High density lipoprotein particle size distribution in subjects with obstructive jaundice', *J Lipid Res*, 1988, 29:121-135
68. Clay, M. A., Hopkins, G. J., Ehnholm, C. P. and Barter, P. J., 'The rabbit as an animal model of hepatic lipase deficiency', *Biochimica et Biophysica Acta*, 1989, 1002:173-181
69. Hopkins, G. J. and Barter, P. J., 'Apolipoprotein A-I inhibits transformation of high density lipoprotein subpopulations during incubation of human plasma', *Atherosclerosis*, 1989, 75:73-82
70. Meyer, B. J., Ha, Y. C. and Barter, P. J., 'Effects of experimental hypothyroidism on the distribution of lipids and lipoproteins in the plasma of rats', *Biochimica et Biophysica Acta*, 1989, 1004:73-79
71. Barter, P. J., Chang, L. B. F., Newnham, H. H., Rye, K-A., and Rajaram, O. V., 'The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high-density lipoproteins', *Biochimica et Biophysica Acta*, 1990, 1045:81-89
72. Barter, P. J., Chang, L. B. F. and Rajaram, O. V., 'Sodium oleate dissociates the heteroexchange of cholesteryl esters and triacylglycerol between HDL and triacylglycerol-rich lipoproteins', *Biochimica et Biophysica Acta*, 1990, 1047:294-29
73. Barter, P. J., Chang, L. B. F. and Rajaram, O. V., 'Sodium oleate promotes the redistribution of cholesteryl esters from high to low density lipoproteins', *Atherosclerosis*, 1990, 84:13-24
74. Clay, M. A., Rye, K-A. and Barter, P. J., 'Evidence in vitro that hepatic lipase reduces the concentration of apolipoprotein A-I in rabbit high-density lipoproteins', *Biochimica et Biophysica Acta*, 1990, 1044:50-56
75. Newnham, H. H. and Barter, P. J., 'Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma', *Biochimica et Biophysica Acta*, 1990, 1044:57-64
76. Newnham, H. H., Hopkins, G. J., Devlin, S. and Barter, P. J., 'Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma', *Atherosclerosis*, 1990, 82:167-176
77. Clay, M. A., Newnham, H. H. and Barter, P. J., 'Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro', *Arterioscler Thromb*, 1991, 11:415-422

78. Lagrost, L. and Barter, P. J., 'Effects of various non-esterified fatty acids on the particle size redistribution of high density lipoproteins induced by the human cholesteryl ester transfer protein', *Biochimica et Biophysica Acta*, 1991, 1082:204-210
79. Lagrost, L. and Barter, P. J., 'Effects of various non-esterified fatty acids on the transfer of cholesteryl esters from HDL to LDL induced by the cholesteryl ester transfer protein', *Biochimica et Biophysica Acta*, 1991, 1085: 209-216
80. Meyer, B., Kecorius, E., Barter, P., Fidge, N. and Tetaz, T., 'Application of reversed-phase high-performance liquid chromatography to the separation of apolipoproteins A-IV, A-I and E from rat high-density lipoprotein', *J Chromatog*, 1991, 540:386-391
81. Warren, R. J., Ebert, D. L., Mitchell, A. and Barter, P. J., 'Rabbit hepatic lipase cDNA sequence: low activity is associated with low messenger RNA levels', *J Lipid Res*, 1991, 32:1333-1339
82. Warren, R. J., Ebert, D. L., Mitchell, A. and Barter, P. J., 'The regulation of hepatic lipase and cholesteryl ester transfer protein activity in the cholesterol fed rabbit', *Biochimica et Biophysica Acta*, 1991, 1086:354-358
83. Clay, M. A., Newnham, H. H., Forte, T. M. and Barter, P. J., 'Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL', *Biochimica et Biophysica Acta*, 1992, 1124:52-58
84. Lagrost, L. and Barter, P. J., 'Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: potentiation by oleic acid', *Biochimica et Biophysica Acta*, 1992, 1127:255-262
85. Newnham, H. H. and Barter, P. J., 'Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase', *Biochimica et Biophysica Acta*, 1992, 1125:297-304
86. Rye, K-A., Garrety, K. H. and Barter, P. J., 'Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins', *J Lipid Res*, 1992, 33:215-224
87. Barter, P. J., Rajaram, O. V., Liang, H-Q. and Rye, K-A., 'Relationship between the size and phospholipid content of low density lipoproteins', *Biochimica et Biophysica Acta*, 1993, 1166:135-137
88. Contacos, C., Barter, P. J. and Sullivan, D. R., 'Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidaemia', *Arterioscler Thromb*, 1993, 13:1755-1762
89. Ebert, D. L., Warren, R. J., Barter, P. J. and Mitchell, A., 'Infusion of atherogenic lipoprotein particles increases hepatic lipase activity in the rabbit', *J Lipid Res*, 1993, 34:89-94

90. Rye, K-A., Garrety, K. H. and Barter, P. J., 'Preparation and characterization of spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II', *Biochimica et Biophysica Acta*, 1993, 1167:316-325
91. Liang, H-Q., Rye, K-A. and Barter, P. J., 'Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins', *J Lipid Res*, 1994, 35:1187-1199
92. Rye, K-A. and Barter, P. J., 'The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins', *J Biol Chem*, 1994, 269:10298-10303
93. Cockerill, G. W., Rye, K-A., Gamble, J. R., Vadas, M. A. and Barter, P. J., 'High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules', *Arterioscler, Thromb Vasc Biol*, 1995, 15:1987-1994
94. Liang, H-Q., Rye, K-A. and Barter, P. J., 'Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools', *Biochimica et Biophysica Acta*, 1995, 1257:31-37
95. Rye, K-A., Hime, H. J. and Barter, P. J., 'The influence of cholesteryl ester transfer protein on the composition, size and structure of spherical, reconstituted high density lipoproteins', *J Biol Chem*, 1995, 270:189-196
96. Clay, M. A. and Barter, P. J., 'Formation of new HDL particles from lipid-free apolipoprotein A-I', *J Lipid Res*, 1996, 37:1722-1732
97. Kee, P., Bais, R., Sobocki, S. K., Bramford, S., Rye, K-A. and Barter, P. J., 'Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E', *Ann Clin Biochem*, 1996, 33:119-126
98. Liang, H-Q., Rye, K-A. and Barter, P. J., 'Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase', *J Lipid Res*, 1996, 37:1962-1970
99. Rye, K-A., Hime, N. and Barter, P. J., 'The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins', *J Biol Chem*, 1996, 271:4243-4250
100. Nestel, P., Simons, L., Barter, P., Clifton, P., Colquhoun, D., Hamilton-Craig, I., Sikaris, K. and Sullivan, D., 'A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin', *Atherosclerosis*, 1997, 129:231-239
101. Rye, K-A., Hime, N. J. and Barter, P. J., 'Evidence that CETP-mediated reductions in reconstituted high density lipoprotein size involve particle fusion', *J Biol Chem*, 1997, 272:5953-5960

102. Ashby, D. T., Rye, K-A., Clay, M. A., Vadas, M. A., Gamble, J. and Barter, P. J., 'Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells', *Arterioscler, Thromb Vasc Biol*, 1998, 18:1450-1455
103. Contacos, C., Barter, P. J., Vrga, L. and Sullivan, D. R., 'Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin', *Atherosclerosis*, 1998, 141:87-98
104. Hime, N. J., Barter, P. J. and Rye, K-A., 'The influence of apolipoprotein on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol', *J Biol Chem*, 1998, 273:27191-27199
105. James, M. J., Van Reyk, D., Rye, K-A., Dean, R. T., Cleland, L. G., Barter, P. J. and Jessup, W., 'Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized', *Lipids*, 1998, 33:1115-1121
106. Rye, K-A., Jauhiainen, M., Barter, P. J. and Ehnholm, C., 'Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein', *J Lipid Res*, 1998, 39:613-622
107. Tonkin, A., Aylward, P., Colquhoun, D., Glasziou, P., Harris, P., MacMahon, S., Magnus, P., Newel, D., Nestel, P., Sharpe, N., Hunt, D., Shaw, J., Simes, R., Thompson, P., Thompson, A., West, M. White, H. Simes, S., Haque, W., Caleo, S., Hall, J., Martin, A., Mulray, S., Barter, P., Beilin, L., Collins, R., McNeil, J., Meler, P., Willmontt, H., Smithers, D., Wallace, P., Sullivan, D., Keech, A., 'Prevention of cardiovascular events and death with pravastatin in patinets with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med, 1998, 339, 1349-1357
108. Xia, P., Gamble, J. R., Rye, K-A., Wang, L., Hii, C. S. T., Cockerill, P., Khew-Goodall, Y., Bert, A. G., Barter, P. J. and Vadas, M. A., 'Tumor necrosis factor- $\alpha$  induces adhesion molecule expression through the sphingosine kinase pathway', *Proc Nat Acad Sci*, 1998, 95:14196-14201
109. Baker, P. W., Rye, K-A., Gamble, J. R., Vadas, M. A. and Barter, P. J., 'Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical cell endothelial cells', *J Lipid Res*, 1999, 40:345-353
110. Clay, M. A., Cehic, D. A., Pyle, D. H., Rye, K-A. and Barter, P. J., 'Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II', *Biochem J*, 1999, 337:445-451
111. Xia, P., Vadas, M. A., Rye, K-A., Barter, P. J. and Gamble, J. R., 'High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway', *J Biol Chem*, 1999, 274:33143-33147

112. Barter, P. J. and O'Brien, R. C., 'Achievement of target plasma cholesterol levels in hypercholesterolemic patients being treated in general practice', *Atherosclerosis*, 2000, 149:199-205
113. Baker, P. W., Rye, K-A., Gamble, J. R., Vadas, M. A. and Barter, P. J., 'Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression', *J Lipid Res*, 2000, 41:1261-1267
114. Clay, M. A., Pyle, D. H., Rye, K-A. and Barter, P. J., 'Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase', *J Biol Chem*, 2000, 275:9019-9025.
115. Ashby D, Gamble J, Vadas M, Fidge N, Siggins S, Rye K-A and Barter PJ. 'Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression', *Atherosclerosis*, 2001, 154:113-121.
116. Clay MA, Pyle DH, Rye K-A, Vadas MA, Gamble JR and Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins', *Atherosclerosis*, 2001, 157:23-29.
117. Hime NJ, Barter PJ and Rye K-A. Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II', *Biochemistry*, 2001, 40: 5496-5505.
118. Kee P, Rye K-A, Taylor JL, Barrett, PH and Barter PJ. Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits. *Arterioscler, Thromb Vasc Biol*, 2002, 22:1912-1917.
119. Rye, K-A., Duong, M., Psaltis, M. K., Curtiss, L. K., Bonnet, D. J., Stocker, R. and Barter, P. J., 'Evidence that phospholipids play a key role in pre- $\beta$  apoA-I formation and high-density lipoprotein remodelling', *Biochemistry*, 2002, 41:12538-12545.
120. Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ and Rye K-A. Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. *Biochemistry*, 2003, 42: 13778-137785.
121. Rye K-A, Wee K, Curtiss L, Bonnet D and Barter P. Apolipoproteins A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoproteins A-I formation. *J Biol Chem*, 2003, 278:22530-22536.
122. Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P and Tonkin A. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol

and high-density lipoprotein cholesterol: results from the LIPID study. *Eur Heart J*, 2004, 25: 771-777.

123. Hime NJ, Drew KJ, Hahn C, Barter PJ and Rye K.-A. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted HDL phospholipid and triacylglycerol in an isoform dependent manner. *Biochemistry*, 2004, 43: 12306-12314.
124. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D and Raza A. Effects of switching statins on achievement of lipid goals: measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. *Am Heart J*, 2004, 147:705-712.
125. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V and Grundy SM. Relation between atherogenic dyslipidemia and the adult treatment program-III definition of metabolic syndrome (Genetic epidemiology of metabolic syndrome project). *Am J Cardiol*, 2004, 95:194-198.
126. Wadham, C., Albanese, N., Roberts, J., Wang, L., Bagley, C.J., Gamble, J.R., Rye, K.-A., Barter, P.J., Vadas, M.A., and Xia, P. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. *Circulation*, 2004, 109:2116-2122.
127. Nicholls, S.J., Drummond, G.R., Rye, K.-A., Dusting, G.J. and Barter, P.J. Reconstituted high density lipoproteins inhibit the pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. *Circulation*, 2005, 111: 1543-1550.
128. LaRosa, JC, Grundy, SM, Waters, DD, Shear, C, Barter, P, Fruchart, JC, Gotto, AM, Greten, H, Kastelein, JJ, Shepherd, J, and Wenger, NK Intensive lipid lowering with atorvastatin in patients with stable coronary disease *N Eng J Med*, 2005, 352:1425-1435.
129. Stender S, Schuster H, Barter P, Watkins C, and Kallend D Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolemic patients with or without the metabolic syndrome in the MERCURY I trial *Diabetes Obes Metab*, 2005, 7:430-438.
130. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye K-A, Bao S, Barter PJ. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits *Arterioscler Thromb Vasc Biol*, 2005, 25:2416-2421.
131. Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot T, Ma Q, Sharma SS, Montgomery, DS, Middleton, LT, Sundseth, SS, Mooser, V, Grundy, SM, Farrer LA. Multiple QTLs influencing triglyceride and HDL and total

cholesterol levels identified in families with atherogenic dyslipidemia *J Lipid Res*, 2005, 46:2202-2213.

132. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen M R, Forder P, Pillai A, D T, Glasziou P, Drury P, Kesaniemi Y A, Sullivan D, Hunt D, and Colman C, D'emden M, Whiting M, Ehnholm C, Laakso M (on behalf of the field study writing committee). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial *Lancet*, 2005, 366:1849-1861.
133. Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; Field study Investigators. Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics of short-term effects of fenofibrate *Cardiovasc Diabetol*, 2005;22:13.
134. Hime NJ, Drew KJ, Wee K, Barter PJ, and Rye K-A. Formation of high density lipoproteins containing both apolipoprotein A -I and A -II in the rabbit *J Lipid Res*, 2006, 47:115-122.
135. Rye K-A, Bright R, Psaltis M and Barter PJ. Regulation of reconstituted high density lipoprotein structure and remodelling by apolipoprotein E *J Lipid Res*, 2006, 47:1025-1036.
136. Tso C, Martinic G, Fan WH, Rogers C, Rye K-A, and Barter PJ. High – Density lipoproteins enhance progenitor-mediated endothelium repair in mice *Arterioscler Thromb Vasc Biol*, 2006, 26:1144-1149.
137. Kee P, Caiazza D, Rye K-A, Barrett PH, Morehouse LA, Barter PJ. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits *Arterioscler Thromb Vasc Biol*, 2006, 26:884-890.
138. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, Larosa J, Grundy S and Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study *Diabetes Care*, 2006, 29:1220-1226.
139. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, Rye KA, Barter PJ, Celermajer DS Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function *J Am Coll Cardiol*, 2006, 48:715-720.
140. Waters, DD, LaRosa, JC, Barter, P, Fruchart, JC, Gotto, AM, Jr, Carter, R, Breazna, A, Kastelein, JJ, Grundy, SM Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease (Treating to New Targets) study *J Am Coll Cardiol*, 2006, 48:1793-1799.
141. Deedwania, P, Barter, P, Carmena, R, Fruchart, JC, Grundy, SM, Haffner, S, Kastelein, JJ, LaRosa, JC, Schachner, H, Shepherd, J,



- Waters, DD Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study *Lancet*, 2006, 368:919-928.
142. Nobecourt, E, Davies, MJ, Brown, BE, Curtiss, LK, Bonnet, DJ, Charlton, F, Januszewski, AS, Jenkins, AJ, Barter, PJ and Rye, K-R The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:chacyltransferase *Diabetologia*, 2007, 50:643-653.
  143. Barter P, McPherson YR, Song K, Antero Kesaniemi Y, Mahley R, Waeber G, Bersot T, Mooser V, Waterworth D, Grundy SM Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia *J Clin Endocrinol Metab*, 2007, 92:2041-2045
  144. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML Effect of Torcetrapib on carotid atherosclerosis in familial hypercholesterolemia *N Engl J Med*, 2007, 356:620-1630.
  145. Nunn AV, Bell J and Barter P The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in meta balance *Nucl Recept*, 2007 May 25: 5:1
  146. Skropeta D, Settasatian C, McMahon MR, Shearston KD, Caiazza D, McGrath KC, Jin W, Rader DJ, Barter PJ, Rye KA N-glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins *J Lipid Res*, 2007, 48:2047-2057
  147. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C, for the treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events *N Engl J Med*, 2007, 357: 1301-1310.
  148. Balkau, B, Deanfield JE, Desprès, Bassand J-P, Fox KAA, Smith SC, Barter PJ, Tan CE, van Gaal L, Wittchen H-U, Massien C, Haffner SM International day for the evaluation of abdominal obesity (IDEA) A study of waist circumference, cardiovascular disease and diabetes mellitus in 168,000 primary care patients in 63 countries *Circulation*, 2007, 116:1942-1951.
  149. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon, J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR and Brewer B for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk of coronary events *N Engl J Med*, 2007, 357: 2109-2122.
  150. Barter PJ, Puranik R and Rye KA New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease *Curr Cardiol Rep*, 2007, 9:493-495.

151. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye K-A, George PM and Lambert G Identification and characterisation of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa *Atherosclerosis*, 2008, 196:659-666.
152. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, Celermajer DS and Rye KA Low doses apolipoprotein A-I rescues carotid arteries from inflammation in vivo *Atherosclerosis*, 2008, 196: 204-247.
153. Settasatian N, Barter PJ and Rye K-A Remodelling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein *J Lipid Res*, 2008, 49:115-126.
154. Stirnadel H, Lin X, Ling H, Song K, Barter P, Kesaniemi YA, Mahley R, McPherson R, Waeber G, Bersot T, Cohen J, Grundy S, Mitchell B, Mooser V, Waterworth D Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: The GEMS Study *Atherosclerosis*, 2008, 197: 868-876.
155. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M, Luben R, Sims M, Hadley D, McArdle W, Barter P, Kesaniemi YA, Mahley RW, McPherson R, Grundy SM; Wellcome Trust Case Control Consortium, Bingham SA, Khaw KT, Loos RJ, Waeber G, Barroso I, Strachan DP, Deloukas P, Vollenweider P, Wareham NJ, Mooser V. LDL-cholesterol concentrations: a genome-wide association study. *Lancet*. 2008;371:483-491.
156. Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ and Rye K-A Effects of cross-link breakers, glycation inhibitors and insulin sensitizers on HDL function and the non-enzymatic glycation of apolipoprotein A-I *Diabetologia*, 2008, 51:1008-1017.
157. Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye K-A and Barter PJ Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment *Clin Chem*, 2008, 54:1038-1043.
158. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, Demicco DA, Breazna A, Larosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. *J Am Coll Cardiol*, 2008, 51:1938-1943.
159. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*, 2008, 117:3002-3009

160. Patel S, Puranik R, Nakhla S, Lundman P, Stocker R, Wang XS, Lambert G, Rye KA, Barter PJ, Nicholls SJ, Celermajer DS. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. *Atherosclerosis*. 2009;204:424-428
161. Ling H, Waterworth DM, Stirnadel HA, Pollin TI, Barter PJ, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Cohen JC, Grundy SM, Mooser VE, Mitchell BD. Genome-wide Linkage and Association Analyses to Identify Genes Influencing Adiponectin Levels: The GEMS Study. *Obesity*. 2009;17:737-744
162. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS, Kingwell BA. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. *J Am Coll Cardiol*. 2009;53:962-971.
163. McGrath KC, Li XH, Puranik R, Liong EC, Tan JT, Dy VM, Di Bartolo B, Barter PJ, Rye KA, Heather AK. Role of 3{beta}-Hydroxysteroid- $\Delta^24$  Reductase in Mediating Antiinflammatory Effects of High-Density Lipoproteins in Endothelial Cells. *Arterioscler Thromb Vasc Biol*. 2009; 29:877-882
164. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; for the FIELD study investigators. Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate. *Arterioscler Thromb Vasc Biol*. 2009; 29:950-955
165. Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ, Jiang F. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. *Free Radic Res*. 2009 Jun 10:1-11.
166. Cannon CP, Danksy HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Design of the DEFINE trial: determining the Efficacy and tolerability of CETP Inhibition with AnacEtrapib. *Am Heart J*. 2009;158:513-519.
167. Grover SA; Kaouache M, Joseph L, Barter P, Davignon . Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. *Arch Int Med*. 2009; 169:1775-1780
168. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy

and safety of dalcetrapib in patients with recent acute coronary syndrome. *Am Heart J.* 2009;158:896-901.

169. Richards JB, Waterworth D, O'Rahilly S, Hivert MF, Loos RJ, Perry JR, Tanaka, T, Timpson NJ, Semple RK, Soranzo N, Song K, Rocha N, Grundberg E, Dupuis J, Florez JC, Langenberg C, Prokopenko I, Saxena R, Sladek R, Aulchenko Y, Evans D, Waeber G, Erdmann J, Burnett MS, Sattar N, Devaney J, Willenborg C, Hingorani A, Witteman JC, Vollenweider P, Glaser B, Hengstenberg C, Ferrucci, L, Melzer D, Stark K, Deanfield J, Winogradow J, Grassl M, Hall AS, Egan JM, Thompson JR, Ricketts SL, König IR, Reinhard W, Grundy S, Wichmann HE, Barter P, Mahley R, Kesaniemi YA, Rader DJ, Reilly MP, Epstein SE, Stewart, AF, Van Duijn CM, Schunkert H, Burling K, Deloukas P, Pastinen T, Samani NJ, McPherson R, Davey Smith G, Frayling TM, Wareham NJ, Meigs JB, Mooser V, Spector TD; GIANT Consortium. A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels. *PLoS Genet.* 2009 Dec;5(12):e1000768. Epub .
170. Nicholls SJ; Brandrup-Wognsen G; Palmer, M; Barter P. Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin versus Rosuvastatin versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). *Am J Cardiol.* 2010 105: 69-76
171. Nobécourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins, AJ, Dusting GJ, Bonnet DJ, Curtiss LK, Barter PJ, Rye KA. Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. *Arterioscler Thromb Vasc Biol.* 2010;30:766-772
172. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence That Niacin Inhibits Acute Vascular Inflammation and Improves Endothelial Dysfunction Independent of Changes in Plasma Lipids. *Arterioscler Thromb Vasc Biol.* 2010;30:968-975
173. Laurila PP, Naukkarinen J, Kristiansson K, Ripatti S, Kauttu T, Silander K, Salomaa V, Perola M, Karhunen PJ, Barter PJ, Ehnholm C, Peltonen L. Genetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2010;30:346-352
174. Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G. The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro. *Arterioscler Thromb Vasc Biol.* 2010; 30:246-252
175. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. *J Lipid Res.* 2010; 51: 1546–1553
176. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, Berrettini W, Knouff, CW, Yuan X, Waeber G, Vollenweider P, Preisig M, Wareham NJ, Zhao JH, Loos RJ, Barroso I, Khaw KT, Grundy S, Barter P, et al. Meta-analysis and imputation refines the association of 15q25

with smoking quantity. *Nat Genet.* 2010; 42:436-440.

177. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, Grarup N, Sparsø T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Ruccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010;42:105-116.
178. Fryirs MA, Barter PJ, Appavaroo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic {beta}-cell insulin secretion. *Arterioscler Thromb Vasc Biol.* 2010; 30:1642-1648.
179. Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC; on behalf of the FIELD study investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. *Diabetologia.* 2010; 53:1846-1855
180. Patel S, Di Bartolo BA, Nakhla S, Heather AK, Mitchell TW, Jessup W, Celermajer DS, Barter PJ, Rye KA. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. *Atherosclerosis.* 2010; 212:392-397
181. Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, Heather AK, Barter PJ, Rye KA. High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo. *Arterioscler Thromb Vasc Biol.* 2010; 30:1773-1778
182. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, Aulchenko YS, Zhang W, Yuan X, Lim N, Luan J, Ashford S, Wheeler E, Young EH, Hadley D, Thompson JR, Braund PS, Johnson T, Struchalin M, Surakka I, Luben R, Khaw KT, Rodwell SA, Loos RJ, Boekholdt SM, Inouye M, Deloukas P, Elliott P, Schlessinger D, Sanna S, Scuteri A, Jackson A, Mohlke KL, Tuomilehto J, Roberts R, Stewart A, Kesäniemi YA, Mahley RW, Grundy SM; Wellcome Trust Case Control Consortium, McArdle W, Cardon L, Waeber G, Vollenweider P, Chambers JC, Boehnke M, Abecasis GR, Salomaa V, Järvelin MR, Ruukonen A, Barroso I, Epstein SE, Hakonarson HH, Rader DJ, Reilly MP, Witteman JC, Hall AS, Samani NJ, Strachan DP, Barter P, van Duijn CM, Kooner JS, Peltonen L, Wareham NJ, McPherson R, Mooser V, Sandhu MS. Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. *Arterioscler Thromb Vasc Biol.* 2010; 30:2264-2276
183. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y,

- Barter P; the DEFINE Investigators. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. *N Engl J Med.* 2010; 363:2406-2415
184. Arsenault BJ, Barter P, Demicco DA, Bao W, Preston GM, Larosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. *J Am Coll Cardiol.* 2010; 57:63-69.
  185. Tabet F, Lambert G, Cuesta Torres LF, Hou L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ, Rye KA. Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoprotein Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. *Arterioscler Thromb Vasc Biol.* 2011; 31:1192-1200.
  186. Reimers GJ, Jackson CL, Rickards J, Chan PY, Cohn JS, Rye KA, Barter PJ, Rodgers KJ. Inhibition of Rupture of Established Atherosclerotic Plaques by Treatment with Apolipoprotein A-I. *Cardiovasc Res.* 2011; 91:37-44.
  187. Waters DD, Ho JE, Demicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. *J Am Coll Cardiol.* 2011; 57:1535-1545.
  188. Nicholls SJ, Borgman M, Nissen SE, Raichlen JS, Ballantyne C, Barter P, John Chapman M, Erbel R, Libby P. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin). *Curr Med Res Opin.* 2011;27:1119-1129
  189. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. *JAMA.* 2011;305:2556-2564.
  190. Di Bartolo BA, Nicholls SJ, Bao S, Rye KA, Heather AK, Barter PJ, Bursill C. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. *Atherosclerosis.* 2011; 217:395-400.
  191. Di Bartolo BA, Vanags LZ, Tan JT, Bao S, Rye KA, Barter PJ, Bursill CA. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. *Lipids Health Dis.* 2011; 10:224
  192. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial.

Circulation. 2011;124:555-562

193. Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, Demicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, Larosa JC, Pedersen TR, Kastelein JJ. The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the TNT and IDEAL Prospective Studies. *Circ Cardiovasc Genet.* 2012;5:51-57.
194. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med.* 2011; 365:2078-2087.
195. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. *Atherosclerosis.* 2011;219:728-733.
196. Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Wong NC, Borgman MR, Nissen SE. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. *Cardiovasc Drugs Ther.* 2012; 26:181-187.
197. Tso C, Rye KA, Barter P. Phenotypic and functional changes in blood monocytes following adherence to endothelium. *PLoS One.* 2012;7(5):e37091.
198. Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. *Nutr Metab Cardiovasc Dis.* 2012; 22:697-703.
199. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; the dal-OUTCOMES Investigators. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med.* 2012; 367:2089-2099
200. Wu BJ, Chen K, Shrestha S, Ong KL, Barter PJ, Rye KA. High Density Lipoproteins Inhibit Vascular Endothelial Inflammation by Increasing 3 $\beta$ -Hydroxysteroid- $\Delta$ 24 Reductase Expression and Inducing Heme Oxygenase-1. *Circ Res.* 2012 Nov 4. [Epub ahead of print]
201. Barter PJ, Rye KA, Beltangady MS, Ports WC, Duggan WT, Boekholdt SM, Demicco DA, Kastelein JJ, Shear CL. Relationship between atorvastatin dose and the harm caused by torcetrapib. *J Lipid Res.* 2012; 53:2436-2442
202. Wu BJ, Chen K, Barter PJ, Rye KA. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. *Circulation.* 2012; 125:150-158
203. Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR,

- Barter PJ, Keech AC; the FIELD study investigators. Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. *J Clin Endocrinol Metab.* 2012; 97:4701-4708.
204. Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. *J Lipid Res.* 2013; 54:467-472.
205. Wu BJ, Chen K, Shrestha S, Ong KL, Barter PJ, Rye KA. High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3 $\beta$ -hydroxysteroid- $\Delta$ 24 reductase expression and inducing heme oxygenase 1. *Circ Res.* 2013; 112:278-288.
206. Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA. *Diabetes Obes Metab.* 2013; 15:629-641.
207. Karlson BW, Nicholls SJ, Lundman P, Palmer MK, Barter PJ. Achievement of 2011 European low density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dL or >50% reduction in high-risk patients: results from VOYAGER. *Atherosclerosis.* 2013;228:265-269.
208. Schwartz GG, Olsson AG, Barter PJ. Dalcetrapib in patients with an acute coronary syndrome. *N Engl J Med.* 2013; 368:869-870.
209. Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, St John J, Wolski K, Uno K, Kataoka Y, Nicholls SJ. Factors underlying regression of coronary atheroma with potent statin therapy. *Eur Heart J.* 2013; 34:1818-1825.
210. Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. Trends in C Reactive Protein Levels in US Adults From 1999 to 2010. *Am J Epidemiol.* 2013; 177:1430-1442
211. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. *Ann Epidemiol.* 2013; 23:80-86
212. Chapman MJ, Giral P, Barter PJ. The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER. *Eur Heart J.* 2013; 34:1318-1320.
213. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after



- maximally intensive statin therapy. *Circulation*. 2013;128:2395-2403.
214. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. *Eur Heart J*. 2013;34:3182-3190.
  215. Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. Trends in C-reactive protein levels in US adults from 1999 to 2010. *Am J Epidemiol*. 2013;177:1430-1442.
  216. Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, St John J, Wolski K, Uno K, Kataoka Y, Nicholls SJ. Factors underlying regression of coronary atheroma with potent statin therapy. *Eur Heart J*. 2013;34:1818-1825.
  217. Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE-ME IAA. *Diabetes Obes Metab*. 2013;15:629-641.
  218. Palmer MK, Nicholls SJ, Lundman P, Barter PJ, Karlson BW. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. *Eur J Prev Cardiol*. 2013;20:1080-1087.
  219. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. *Eur Heart J*. 2013; 34:3182-3190
  220. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate with Coronary Atheroma Regression and Cardiovascular Events Following Maximally Intensive Statin Therapy. *Circulation*. 2013; 128:2395-2403
  221. Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. *Am J Cardiol*. 2014; 113:76-83.
  222. Wu BJ, Ong KL, Shrestha S, Chen K, Tabet F, Barter PJ, Rye KA. Inhibition of arthritis in the Lewis Rat by apolipoprotein A-I and reconstituted high density lipoproteins. *Arterioscler Thromb Vasc Biol*. 2014;34:543-551

223. McGrath KC, Li XH, Whitworth PT, Kasz R, Tan JT, McLennan SV, Celermajer DS, Barter PJ, Rye KA, Heather AK. High density lipoproteins improve insulin sensitivity in high fat diet fed mice by suppressing hepatic inflammation. *J Lipid Res.* 2014;55:421-430.
224. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia: Executive summary. Expert Panel on Dyslipidemia. *Atherosclerosis.* 2014; 232:410-413.
225. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C, Prado-Lourenco L, Levin MG, Thacker S, Sethupathy P, Barter PJ, Remaley AT, Rye KA. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. *Nat Commun.* 2014; 5:3292-
226. Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. The Relationship between Total Bilirubin Levels and Total Mortality in Older Adults: The United States National Health and Nutrition Examination Survey (NHANES) 1999-2004. *PLoS One.* 2014;9(4):e94479.
227. Ong KL, Waters DD, Messig M, Demicco DA, Rye KA, Barter PJ. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study). *Am J Cardiol.* 2014;113:1593-1598.
228. Arsenault BJ, Boekholdt SM, Mora S, Demicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). *Am J Cardiol.* 2014;113:1378-1382.
229. Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. *Eur Heart J Cardiovasc Imaging.* 2014;15:380-388.
230. Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; the DEFINE Investigators. Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. *J Cardiovasc Pharmacol Ther.* 2014; 19:543-549
231. Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD; for the Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary

syndromes: a randomized trial. *Eur Heart J.* 2014; 35:3277-3286

232. Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD. Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. *J Am Coll Cardiol.* 2014;63:2365-2373.
233. Cochran BJ, Basisoendial RJ, Hou L, Glaros EN, Rossy J, Thomas SR, Barter PJ, Rye KA. Apolipoprotein A-I increases insulin secretion and production from pancreatic  $\beta$ -cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism. *Arterioscler Thromb Vasc Biol.* 2014; 34:2261-2267.
234. Ong KL, McClelland RL, Rye KA, Cheung BM, Post WS, Vaidya D, Criqui MH, Cushman M, Barter PJ, Allison MA. The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis.* 2014; 236:257-262.
235. Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD. Can HDL Infusions Significantly QUICKen Atherosclerosis REGression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. *Eur Heart J.* 2014; 35:3277-3286
236. Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. *J Cardiovasc Pharmacol Ther.* 2014; 19:543-549.
237. Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004. *PLoS One.* 2014 Apr 11;9(4):e94479.
238. Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with

stable coronary artery disease treated with atorvastatin (from the treating to new targets study). *Am J Cardiol.* 2014; 113:1593-1598.

239. Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. *PLoS One.* 2014 22;9(12):e114519.
240. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. *JACC Cardiovasc Imaging.* 2014; 7:1013-1022.
241. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. *Arterioscler Thromb Vasc Biol.* 2014; 34:2465-2472.
242. Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nissen SE, Nicholls SJ. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. *Diabetes Care.* 2014; 37:3114-3120.
243. Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, Grainger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody GJ, Nissen SE. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. *Am Heart J.* 2015; 170:1061-1069.
244. Bisoendial R, Tabet F, Tak PP, Petrides F, Cuesta Torres LF, Hou L, Cook A, Barter PJ, Weninger W, Rye KA. Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis. *Arterioscler Thromb Vasc Biol.* 2015; 35:2443-2450.
245. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER metaanalysis. *Eur J Prev Cardiol.* 2016 May;23(7):744-7
246. Barter PJ, Nicholls SJ, Kastelein JJ, Rye KA. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. *Circulation.* 2015; 132:423-432.

247. Wu BJ, Shrestha S, Ong KL, Johns D, Dunn LL, Hou L, Barter PJ, Rye KA. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis. *Int J Cardiol.* 2015; 199:204-212.
248. Ong KL, Ding J, McClelland RL, Cheung BM, Criqui MH, Barter PJ, Rye KA, Allison MA. Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis. *Atherosclerosis.* 2015; 241:664-670.
249. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. *Atherosclerosis.* 2015; 241:450-454.
250. Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. *Diabetologia.* 2015; 58:2035-2044.
251. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet.* 2015; 386:452-460.
252. Ong KL, Ding J, McClelland RL, Cheung BM, Criqui MH, Barter PJ, Rye KA, Allison MA. Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis.* 2015; 239:386-392.
253. Sullivan DR, Watts GF, Nicholls SJ, Barter P, Grenfell R, Chow CK, Tonkin A, Keech A. Clinical guidelines on hyperlipidaemia: recent developments, future challenges and the need for an Australian review. *Heart Lung Circ.* 2015; 24:495-502.
254. Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. *J Clin Lipidol.* 2015; 9:65-71.
255. Wu BJ, Shrestha S, Ong KL, Johns D, Hou L, Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit. *Arterioscler Thromb Vasc Biol.* 2015; 35:628-636.
256. Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, Tan CE, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alm eras N, Haffner SM, Balkau B, Despr es JP; INSPIRE ME IAA Investigators. Usefulness of measuring both body mass index and waist

- circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). *Am J Cardiol.* 2015; 115:307-315.
257. Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. *Diabetologia.* 2015; 58:464-473
  258. Borel AL, Nazare JA, Smith J, Aschner P, Barter P, Van Gaal L, Eng Tan C, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alm eras N, Haffner SM, Balkau B, Despr es JP. Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance. *Int J Obes (Lond).* 2015; 39:495-501.
  259. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. *Am J Cardiol.* 2016; 117:1444-1448
  260. Sultana A, Cochran BJ, Tabet F, Patel M, Torres LC, Barter PJ, Rye KA. Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I. *FASEB J.* 2016 Mar 10. [Epub ahead of print]
  261. Tabet F, Cuesta Torres LF, Ong KL, Shrestha S, Choteau SA, Barter PJ, Clifton P, Rye KA. High-Density Lipoprotein-Associated miR-223 Is Altered after Diet-Induced Weight Loss in Overweight and Obese Males. *PLoS One.* 2016 Mar 10;11(3):e0151061.
  262. Puranik R, Bao S, Bonin AM, Kaur R, Weder JE, Casbolt L, Hambley TW, Lay PA, Barter PJ, Rye KA. A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. *Cell Biosci.* 2016 Feb 6;6:9. doi: 10.1186/s13578-016-0076-8. eCollection 2016
  263. Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Hu B, Uno K, Kataoka Y, Herrman JP, Merkely B, Borgman M, Nissen SE. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. *Am J Cardiovasc Drugs.* 2016; 16:55-65.
  264. Bisoendial R, Tabet F, Tak PP, Petrides F, Cuesta Torres LF, Hou L, Cook A, Barter PJ, Weninger W, Rye KA. Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis. *Arterioscler Thromb Vasc Biol.* 2015;35: 2443-2450.
  265. Siebel AL, Trinh SK, Formosa MF, Mundra PA, Natoli AK, Reddy-Luthmoodoo M, Huynh K, Khan AA, Carey AL, van Hall G, Cobelli C, Dalla-Man C, Otvos JD, Rye KA, Johansson J, Gordon A, Wong NC, Sviridov D, Barter P, Duffy SJ, Meikle PJ, Kingwell BA. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. *Metabolism.*

2016; 65:904-914.

266. Cochran BJ, Ryder WJ, Parmar A, Tang S, Reilhac A, Arthur A, Charil A, Hamze H, Barter PJ, Kritharides L, Meikle SR, Gregoire MC, Rye KA. In vivo PET imaging with [ F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes. *Diabetologia*. 2016; 59:1977-1984.
267. Geronimo FR, Barter PJ, Rye KA, Heather AK, Shearston KD, Rodgers KJ. Plaque stabilizing effects of apolipoprotein A-IV. *Atherosclerosis*. 2016; 251:39-46.
268. Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ.. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. *Eur Heart J Cardiovasc Pharmacother*. 2016; 2:212-217.
269. Cochran BJ, Hou L, Chirackal Manavalan AP, Moore BM, Tabet F, Sultana A, Torres LC, Tang S, Shrestha S, Senanayake P, Patel M, Ryder WJ, Bongers, A, Maraninchi M, Wasinger VC, Westerterp M, Tall AR, Barter PJ, Rye KA. Impact of Perturbed Pancreatic  $\beta$ -cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. *Diabetes*. 2016; 65:3610-3620

270.

*Diabetes*. 2016 Dec;65(12):3610-3620

## Reviews and editorials

1. Calvert GD and Barter PJ. An introduction to the biochemistry and pathophysiology of lipids and lipoproteins, *Clin Biochemist*, 1981, 106-115.
2. Barter PJ, Hopkins GJ and Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins, *Biochem J*, 1982, 208:1-7.
3. Barter PJ. Enzymes involved in lipid and lipoprotein metabolism, *Curr Opin Lipidol*, 1990, 1:518-523.
4. Barter PJ. High density lipoproteins and coronary heart disease, *Aust NZ J Med*, 1991, 21:299-301.
5. Barter PJ. High-density lipoproteins and reverse cholesterol transport, *Curr Opin Lipidol*, 1993, 4:210-217.
6. Barter PJ. Cholesterol and cardiovascular disease: basic science, *Aust NZ J Med*, 1994, 24:83-88.
7. Barter PJ. Plasma lipoproteins and coronary heart disease, *J Cardiovasc Risk*, 1994, 1:193-196.
8. Barter PJ and Rye K-A. High-density lipoproteins and coronary heart disease', *J Cardiovasc Risk*, 1994, 1:217-221.
9. Barter PJ and Rye K-A. Cholesteryl ester transfer protein: its role in plasma lipid transport', *Clin Exper Pharm Physiol*, 1994, 21:663-672.
10. Barter PJ and Rye K-A. High density lipoproteins and coronary heart disease', *Atherosclerosis*, 1996, 121:1-12.
11. Barter PJ and Rye, K-A. Molecular mechanisms of reverse cholesterol transport, *Curr Opin Lipidol*, 1996, 7:82-87.
12. Rye K-A, Clay MA and Barter PJ. Remodelling of high density lipoproteins by plasma factors, *Atherosclerosis*, 1999, 145:227-238.
13. Thompson GR and Barter PJ. Clinical lipidology at the end of the millennium', *Curr Opin Lipidol*, 1999, 10:521-526.
14. Barter P. CETP and atherosclerosis, *Arterioscler, Thromb Vasc Biol*, 2000, 20:2029-2031.
15. Barter PJ. Treating to target with statins, *Atheroscler Supp* 2000, 1:21-25.
16. Thompson GR and Barter PJ. Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease, *Curr Opin Lipidol*, 2000, 11:567-570.
17. Barter P. Anti-atherogenic effects of fibrates in type 2 diabetes, *Curr Cont Trials Cardiovas Med*, 2001, 2:218-220.



18. Barter PJ and Rye K-A. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease, *Curr Opin Lipidol*, 2001, 12:377-382.
19. Watts GF, Dimmitt SB and Barter PJ. Normocholesterolaemic dyslipidaemia: is there a role for fibrates?, *Med J Aust*, 2001, 174:66-67.
20. Barter P. Effects of inflammation on high-density lipoproteins, *Arterioscler Thromb Vasc Biol*, 2002, 22:1062-1063.
21. Barter PJ. Coronary plaque regression: role of low density lipoprotein-apheresis', *J Amer Coll Cardiol*, 2002, 40:228-230.
22. Barter PJ. Gemfibrozil, *J Drug Eval: Cardiovasc Med*, 2002, 1:13-39.
23. Barter PJ. Hugh Sinclair lecture: the regulation and remodelling of HDL by plasma factors, *Atheroscler Supp*, 2002, 3:39-47.
24. Barter PJ, Baker PW and Rye K-A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells', *Curr Opin Lipidol*, 2002, 13:285-288.
25. Barter P. Reconsidering the value of fibrates: lessons from the trials, *Brit J Diabetes Vasc Dis*, 2003, 3:162-167.
26. Barter PJ. Introduction Lipids, inflammation and CVD-understanding the basics to break the atherosclerosis cycle', *Int J Clin Pract*, 2003, 137:2-4.
27. Barter PJ, Brewer HBJr, Chapman MJ, Hennekens CH, Rader DJ and Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis, *Arterioscler Thromb Vasc Biol*, 2003, 23:160-167.
28. Barter P, Kastelein J, Nunn A, Hobbs R and Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions' *Atherosclerosis*, 2003, 168:195-211.
29. Barter P. Metabolic abnormalities: high-density lipoproteins. *Endocrinol Metab Clin North Am*, 2004, 33:393-403.
30. Barter PJ, Nicholls SJ, Rye K-A, Anantharamaiah GM, Navab M, and Fogelman AM. Anti-inflammatory properties of HDL *Circ Res*, 2004, 95:764-772.
31. Rye KA and Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I, *Arterioscler Thromb Vasc Biol*, 2004, 24: 421-428.
32. Barter, P, HDL: a recipe for longevity *Atheroscler Supp* 2004, 5:25-31.
33. Barter PJ. Antiatherogenic properties of fibrates *Arterioscler Thromb Vasc Biol*, 2005, 25:1095-1096.
34. Barter P. Cardioprotective effects of high-density lipoproteins: the evidence strengthens *Arterioscler Thromb Vasc Biol*, 2005, 25:1305-1306.

35. Nicholls SJ, Rye, K-A and Barter PJ. High-density lipoproteins as therapeutic targets *Curr Opin Lipidol*, 2005, 16:345-349.
36. Barter, P, The inflammation: lipoprotein cycle *Atheroscler Supp* 2005, 6:15-20.
37. Barter PJ and Kastelein JP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease *J Amer Coll Cardiol*, 2006, 47:492-499.
38. Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture, P, Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, *et al.* Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty person/ten-country panel *J Intern Med*, 2006, 259:247-258.
39. Barter PJ, and Rye K-A. Cardioprotective properties of fibrates Which fibrate, which patients, what mechanism? *Circulation*, 2006, 113:1553-1555.
40. Barter PJ, and Rye KA. Are we lowering LDL cholesterol sufficiently? *Nat Clin Pract Cardiovasc Med*, 2006, 3:290-291.
41. Barter PJ and Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk *J Intern Med*, 2006, 259:447-454.
42. Barter PJ. Managing diabetic dyslipidaemia-beyond LDL-C: HDL-C and triglycerides *Atheroscler Supp*, 2006, 7:17-21.
43. Barter, PJ and Rye, KA Relationship between the concentration and antiatherogenic activity of high-density lipoproteins *Curr Opin Lipidol*, 2006, 17:399-403.
44. Barter PJ and Rye K-A. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins *Circulation*, 2006, 114:1325-1320.
45. Barter PJ and Rye KA . Homocysteine and cardiovascular disease: is HDL the missing link? *Circ Res*, 2006, 99:565-566.
46. Barter PJ and Shear CL. Aggressive management of obesity in children and young adults: the known challenges and potential opportunities *Clin Pharmacol Ther*, 2007, 81: 627-630.
47. Barter PJ and Rye KA Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? *Arterioscler Thromb Vasc Biol*, 2008, 28:39-46.
48. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. *J Lipid Res*. 2008 Nov 24. [Epub ahead of print]
49. Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight *Arterioscler Thromb Vasc Biol*. 2008;28:1890-1891

50. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 FattyAcid therapy for mixed dyslipidemia. *Am J Cardiol.* 2008, 102:1040-1045.
51. Fryirs M, Barter PJ, Rye KA. Cholesterol metabolism and pancreatic beta-cell function. *Curr Opin Lipidol.* 2009;20:159-164.
52. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. *Eur J Cardiovasc Prev Rehabil.* 2009;16:404-423
53. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. *Am J Cardiol.* 2009 Nov 16;104(10 Suppl):10E-5E.
54. Barter PJ. The Relationship between Cholesteryl Ester Transfer Protein and Cardiovascular Risk. *Clin Chem.* 2010; 56:1547-1549.
55. Barter PJ. The causes and consequences of low levels of high density lipoproteins in patients with diabetes. *Diabetes Metab J.* 2011; 35:101-106.
56. Barter P. HDL-C: Role as a risk modifier. *Atheroscler Suppl.* 2011;12:267-70
57. Rye KA, Barter PJ. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. *Biochim Biophys Acta.* 2011 Oct 19. [Epub ahead of print]
58. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O'Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O'Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S, Trent R; Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society). Familial hypercholesterolaemia: A model of care for Australasia. *Atheroscler Suppl.* 2011 Sep 12. [Epub ahead of print]
59. Barter P, Rye KA. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? *Trends Pharmacol Sci.* 2011;32:694-699.
60. Chan JC, Chan SP, Deerochanawong C, Go RT, Lee KO, Ma RC, Pan CY, Sheu WH, Barter P. Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't know. *Diabetes Res Clin Pract.* 2011;94:1-13.
61. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. *Nat Rev Endocrinol.* 2012; 8:237-245.

62. Barter PJ, Rye KA. Cholesteryl ester transfer protein (CETP) inhibition as a strategy to reduce cardiovascular risk. *J Lipid Res.* 2012; 53:1755-1766.
63. Rye KA, Barter PJ. The inhibition of cholesteryl ester transfer protein: a long and winding road. *J Lipid Res.* 2012; 53:1039-1041.
64. Rye KA, Barter PJ. Cardioprotective functions of HDL. *J Lipid Res.* 2014;55:168-179.
65. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges. *Circulation.* 2013;128:1256-1267.
66. Barter PJ. High density lipoprotein: A therapeutic target in type 2 diabetes. *Endocrinol Metab (Seoul).* 2013; 28:169-177. Review
67. Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. *Circ Res.* 2014; 114:143-156.
68. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High density lipoproteins: a consensus statement from the National Lipid Association. *J Clin Lipidol.* 2013; 7:484-525.
69. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high density lipoprotein function into clinical practice: current prospects and future challenges. *Circulation.* 2013;128:1256-1267.
70. Barter P. Lipoprotein metabolism and CKD: overview. *Clin Exp Nephrol.* 2013 Sep 20. [Epub ahead of print]
71. Barter P.J. High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes. *Endocrinol Metab (Seoul).* 2013; 28:169-177.
72. Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. *Circ Res.* 2014;114:143-156.
73. Rye KA, Barter PJ. Cardioprotective functions of HDLs. *J Lipid Res.* 2014; 55:168-179.
74. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözo Lu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P. Residual macrovascular risk in 2013: what have we learned? *Cardiovasc Diabetol.* 2014; 13:26. [Epub ahead of print]

75. Expert Panel on Dyslipidemia. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia: Executive summary. *Atherosclerosis*. 2014; 232:410-413.
76. Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new-onset diabetes. *Am Heart J*. 2014;167:421-428.
77. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. *J Clin Lipidol*. 2014;8:29-60.
78. Barter PJ, Rye KA, New era of lipid-lowering drugs. *Pharmacol Rev* 2016; 68:458-475.
79. Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. *J Atheroscler Thromb*. 2014; 21:997-1010.
80. Barter PJ, Rye KA. Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence? *Clin Ther*. 2015;37:2716-2731
81. Rye KA, Barter PJ, Brown AJ. Speed kills in more ways than one: Methamphetamine and atherosclerosis. *Atherosclerosis*. 2015;243:654-655.
82. Barter PJ, Tabet F, Rye KA. Reduction in PCSK9 levels induced by anacetrapib: an off-target effect? *J Lipid Res*. 2015;56:2045-2047
83. Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. *Nat Rev Cardiol*. 2016; 13:48-60.
84. Rye KA, Barter PJ, Cochran BJ. Apolipoprotein A-I interactions with insulin secretion and production. *Curr Opin Lipidol*. 2016; 27:8-13.
85. Barter PJ, Rye KA. Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead-Pro. *Arterioscler Thromb Vasc Biol*. 2016; 36:439-441.
86. Barter PJ, Nicholls SJ, Kastelein JJ, Rye KA. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. *Circulation*. 2015 Aug 4;132(5):423-32.
87. Barter PJ, Rye KA. Coronary artery disease: Scavenger receptor class B1 - a target to reduce CHD risk? *Nat Rev Cardiol*. 2016 May;13(5):249-50.
88. Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum, SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiburger T, Genest, J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, Yamashita S; International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society

Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes Endocrinol.* 2016; 4:850-861.

89. Al Rasadi K, Almahmeed W, AlHabib KF, Abifadel M, Farhan HA, AlSifri S,, Jambart S, Zubaid M, Awan Z, Al-Waili K, Barter P. Dyslipidaemia in the Middle East: Current status and a call for action. *Atherosclerosis.* 2016; 252:182-187.

90.

## Letters

- 1 Barter P, Shear CL, Revkin JH. 'Torcetrapib and coronary events – Reply'. *N Eng J Med*, 358:1863-1864.

## Chapters in reference books

- 1 Barter P J. 'HDL metabolism in relation to plasma cholesteryl ester transport', In: *Clinical and Metabolic aspects of High-density Lipoproteins*, Edited by Miller, N E and Miller, G J, Elsevier Science Publishers B V, 1984, pp 167-185.
2. Barter PJ, Hopkins G J and Rajaram OV. 'Enzymes involved in plasma cholesterol transport', In: *Endocrinology and Metabolism, Vol 1 No 3 Lipoprotein Metabolism*, Edited by Shepherd, J, Bailliere Tindall, London, 1987, pp 623-638.
3. Barter PJ. 'Large scale trials of lipid lowering', In: *A Textbook of Preventive Medicine*, Edited by McNeil, J J, King, R W F, Jennings, G L and Powles, J W, Edward Arnold (Australia) Pty Ltd, 1990, pp 150-156.
- 3 Rye K-A and Barter PJ. 'Lipid transfer activities and apolipoproteins', In: *Structure and function of apolipoproteins*, Edited by Rosseneu, M, CRC Press Inc, 1992, pp 401-426.
- 4 Barter PJ and Rye K-A, 'The management of low HDL', In: *Lipoproteins and Coronary Artery Disease*, Edited by Kreisberg, R A and Segrest, J, Blackwell Scientific Publications, Cambridge, Ma, 1993, pp 357-383.
- 5 Barter PJ. 'Practical Biochemistry of Lipids', In: *The Clinician's Handbook on Lipids*, Edited by Simons, L A, Adis International Pty Ltd, 1994, pp 1-19.
- 6 Barter PJ. 'Size exclusion chromatography applied to the analysis of lipoproteins', In: *New Trends in Lipids and Lipoprotein Analyses*, Edited By Perkins, E G and Sebedio, J L, AOCS Press, Champaign, Illinois, 1995, pp 337-346
7. Barter, P J, Clay, M A and Rye, K-A, 'High Density Lipoproteins: The Anti-Atherogenic Fraction', In: *Plasma Lipids and their Role in Disease*, Edited by Barter, P J and Rye, K-A, Harwood Academic Publishers, UK, 1999, pp 85-108.
8. Barter PJ and Rye K-A, 'LCAT', In: *Lipoproteins in Health and Disease*, Edited by Betteridge, D J, Shepherd, J, Roger, D, Illingworth, and Oliver, S, Edward Arnold Limited, London, UK, 1999, pp 261-276.
9. Rye K-A, Clay M A and Barter PJ. 'Overview of Plasma Lipid Transport', In: *Plasma Lipids and their Role in Disease*, Edited by Barter PJ and Rye K-A, Harwood Academic Publishers, UK, 1999, pp 1-16.
10. Baker PW, Rye K-A and Barter PJ. 'Inhibition of the cytokine-induced expression of endothelial cell adhesion molecules by high density

- lipoproteins', In: *Atherosclerosis: Gene expression, cell interactions and oxidation*, Edited by Dean, RT and Kelly DT, Oxford University Press, Oxford New York, 2000, pp283-300.
11. Barter, PJ. 'Effects of statins on HDL and the implications for CHD prevention', In: *Lipids and atherosclerosis Annual 2003*, Martin Dunitz, London, 2003, pp71-88
  12. Barter PJ. 'Overview of HDL and reverse cholesterol transport', In: *Lipids and Atherosclerosis*, Eds: Packard CJ and Rader RJ Taylor & Francis, London, 2006, pp81-92.
  13. Barter PJ and Nicholls SJ. 'Current and emerging therapies in atheroprotection', In: *Mechanisms of vascular disease; a textbook for vascular surgeons* Eds: Fotridge R and Thompson M, Cambridge University, 2007, pp 127-148.
  14. Barter PJ and Rye K-A . High-density lipoprotein structure and metabolism: regulation by cell membrane receptors In: *The year in lipid disorders* Eds: Packard CJ and Wilkie S, Clinical Publishing, Oxford, V1, 2007, pp 93-112.
  15. Barter PJ and Rye K-A . HDL and atherosclerosis, In: *High-density lipoprotein* Ed: Fielding CJ, Wiley-VCH, Weinheim, 2007, pp 491-505.
  16. Barter PJ. Lipid Surrogates: LDL Cholesterol, Non-HDL Cholesterol, apo B, HDL Cholesterol, apo- A-I, ratios, TG, Particle Size and Number. In: *CLINICAL LIPIDOLOGY: A COMPANION TO BRAUNWALD'S HEART DISEASE*, edited by Christie M. Ballantyne, Elsevier Inc, 2008

## Guidelines

1. Barter PJ, Best J, Boyden A, Cooper C, Gillam I, Mansfield P, Nestel P, Parsons M, Ruth, D, Sheerin, N, Sullivan, D, Thompson, P, Tonkin A and Vale M. 'Lipid Management Guidelines – 2001', *Med J Aust Supp*, 2001, 175:S57-S88.
2. Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K, Sullivan D, Thompson P, Vale M, Cooper C, Robinson M and Clune E. National Heart Foundation of Australian and the Cardiac Society of Australia and New Zealand: Position statement on lipid management – 2005 *Heart Lung Circ*, 2005, 14:275-291.



## **Published proceedings of meetings**

1. Barter PJ, Hopkins GJ, Calvert GD and Ha YC. 'A model of plasma esterified cholesterol metabolism: the role of esterified cholesterol transfers and exchanges between plasma lipoproteins', In: *Lipoprotein Kinetics and Modeling*, Edited by Berman, M, Grundy, S M and Howard, B, Academic Press, 1982, pp 351-361.
2. Barter PJ, Rajaram, O V and Calvert GD. 'Triglyceride exchanges and transfers: their role in the kinetics of plasma triglyceride transport', In: *Lipoprotein Kinetics and Modeling*, Edited by Berman, M, Grundy, S M and Howard, B, Academic Press, 1982, pp 245-251.
3. Barter PJ. 'Site of action of LCAT in plasma', In: *Atherosclerosis VI*, Edited by Schettler, G, Gotto, A M, Middelhoff, G, Habenicht, A J R and Jurutka, K R, Springer-Verlag, Berlin, Heidelberg, New York, 1983, pp 423-427.
4. Barter PJ and Hopkins GJ. 'Roles of LCAT and lipid transfer protein in HDL metabolism', In: *Drugs Affecting Lipid Metabolism*, Edited by Paoletti, R, Kritchevsky, D and Holmes, W L, Springer-Verlag, Berlin, Heidelberg, 1987, pp 244-246.
5. Barter PJ, Hopkins GJ and Ha Y C. The role of lipid transfer proteins in plasma lipoprotein metabolism, *Amer Heart J*, 1987, 113:538-542.
6. Barter PJ, Hopkins GJ, Rajaram OV and Rye K-A. 'Factors that induce changes in the particle size of high density lipoproteins', In: *Atherosclerosis VII*, Edited by Fidge, N H and Nestel, P J, Excerpta Medica, Amsterdam, 1986, pp 187-190.
7. Barter PJ, Hopkins GJ and Rajaram O V. 'Metabolic heterogeneity of high density lipoproteins', In: *Proceedings of the Workshop on Lipoprotein Heterogeneity*, Edited by Lippel, K, US Department of Health and Human Services, NIH Publications No 87-2646, 1987, pp 401-417.
8. Barter PJ. 'Abnormalities of cholesteryl ester transfer', In: *Atherosclerosis VIII*, Edited by Crepaldi, G, Gotto, A M, Manzato, E and Baggio, G, Excerpta Medica, Amsterdam, New York, Oxford, 1989, pp 377-380.
9. Barter PJ, Hopkins GJ, Rajaram OV and Rye, K-A. 'Plasma factors involved in the formation of very small HDL particles', In: *High Density Lipoproteins & Atherosclerosis II*, Edited by Miller, N E, Excerpta Medica, Amsterdam – New York – Oxford, 1989, pp 181-188.
10. Barter PJ. 'Plasma factors which transform high density lipoproteins', In: *Disorders of HDL*, Edited by Carlson, L, Smith-Gordon, Nishimura, 1990, pp 31-39.
11. Barter PJ, Chang BF, Newnham HH, Rye K-A and Rajaram OV. 'Roles of lecithin:cholesterol acyltransferase, lipid transfer proteins and nonesterified fatty acids in plasma cholesterol transport', *J Drug Develop*, 1990, 3 (Suppl 1):85-90.

12. Barter P J, Chang LBF and Rajaram OV. 'Factors regulating the distribution of cholesterol between LDL and HDL', *Adv Experiment Med Biol*, 1991, 285:59-64.
13. Barter, P J, 'Role of non-esterified fatty acids in regulating plasma cholesterol transport', *Clin Experiment Pharm and Physiol*, 1991, 18:77-79
14. Barter, P J, 'The substructure of HDL and its relevance to atherosclerosis', In: *Lipoproteins and the Pathogenesis of Atherosclerosis*, Edited by Shepherd, J W, Packard, C J and Brownlie, S M, Excerpta Medica, Amsterdam – London – New York – Tokyo, 1991, pp 97-105.
15. Barter, P J, Nelson, L, Devlin, S and Jenkins, P, 'Effects of acipimox on plasma lipoproteins and hyperlipidemic human subjects', *Atherosclerosis Rev*, 1991, 22:213-216.
16. Barter P J and Rye K-A. 'Role of sodium oleate in modulating the effects of CETP on HDL size and composition', In: *Atherosclerosis IX*, Edited by Stein, O, Eisenberg, S and Stein, Y, R & L Creative Communications Ltd, Tel Aviv, Israel, 1992, pp 75-78.
17. Barter PJ, Liang H-Q, Clay MA and Rye K-A. "The roles of hepatic lipase and cholesteryl ester transfer protein in HDL metabolism", In: *Atherosclerosis X*, Edited by Woodford, F P, Davignon, J and Sniderman, A, Elsevier Amsterdam – Lausanne – New York – Oxford – Shannon – Tokyo, 1995, pp 731-735.
18. Barter PJ. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. *Clin Experiment Pharmacol Physiol*, 1997, 24:286-287.
19. Barter PJ, Rye K-A, Clay MA, Ashby PW, Baker PW, Xia P, Gamble JR and Vadas MA. 'Antiatherogenic effects of high-density lipoproteins: mechanisms', In: *Atherosclerosis XI*, Edited by Jacotot, B, Mathe, D and Fruchart, J-C, Elsevier Amsterdam – Lausanne – New York – Oxford – Shannon – Singapore – Tokyo, 1998, pp 125-133.
20. Barter PJ. Cholesterol management: how to implement best practice. *Euro Heart J*, 2000, 2(Suppl L):L17-L21.
21. Barter PJ. Treating to target with statins. *Atherosclerosis*, 2000, 1:21-5.
22. Lacko A G, Barter P, Ehnholm C and Van Tol A. International symposium on basic aspects of HDL metabolism and disease prevention. *J Lipid Res*, 2000, 41:1695-1699.
23. Barter PJ and Sacks FM. Threshold level or not for low-density lipoprotein cholesterol. *Amer J Managed Care*, 2001, 7:125-131.
24. Shepherd J and Barter P. Lipid-lowering – translating evidence into benefits. *Atherosclerosis Supp*, 2002, 2:1-3.

25. Barter, P Treatment of dyslipidaemia in high-risk patients: too little, too late. *Int J Clin Pract Supp* 2002 130:15-19.
26. Shepard, J, Hunninghake, DB, Barter, PJ, McKenney, JM and Hutchinson, HG Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvasatin, pravastatin, and simvastatin for achieving lipid-lowering goals. *Amer J Cardiol*, 2003, 91:11C-19C.
27. Barter, P 'HDL: a recipe for longevity'. *Atheroscler Suppl*, 2004, 5: 25-31.
28. Barter, P 'Is high-density lipoprotein the protector of the cardiovascular system?' *Eur Heart J Supp*, 2004, 6:A19-A22.
29. Barter, P, 'Global guidelines: national issues', In: *Atherosclerosis XIII – International Congress Series 1262: Internal Medicine*, Edited by Matsuzawa, Y, Kita, T, Nagai, R and Teramoto, T, Elsevier BV, Amsterdam, 2004, pp 184-187.
30. Shepherd J, Hunninghake DB, Barter P, McKenney JM and Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of Rosuvastatin, Atorvastatin, Pravastatin, and Simvastation for achieving lipid-lowering goals *Atheroscler Suppl*, 2004, 5:115-123
31. Barter, P. The inflammation: lipoprotein cycle *Atheroscler Suppl*, 2005, 6:15-20
32. Barter, PJ, Watkins, C, Kallend, D (For the Mercury I Trialist Group). Achievement of apolipoprotein B goal in patients who achieve their low-density lipoprotein cholesterol goal: results of the MERCURY I trial. *Int J Clin Prac*, 2005, 59:3-13.